🔎 Trials Near Me

Utama › Meduloblastoma › Wilayah Columbia

Kajian klinikal Meduloblastoma di Wilayah Columbia

7 kajian untuk Meduloblastoma sedang mencari peserta di lokasi di Wilayah Columbia.

Bandar di Wilayah Columbia

Teks kajian rasmi (Bahasa Inggeris)

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

  • Children's National Hospital, Washington D.C.
Mengambil pesertaFasa 1/2
Umur 1 hingga 25 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07346157

Digoxin Medulloblastoma Study

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
12 Months – 30 Years · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06701812

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 3
Umur 4 hingga 21 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05382338

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05096481

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

  • Children's National Hospital, Washington D.C.
Mengambil peserta
12 Months – 39 Years · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05057702

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

  • Children's National Hospital, Washington D.C.
Mengambil pesertaFasa 1
Umur 4 hingga 30 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06514898

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

  • Children's National Hospital, Washington D.C.
Mengambil pesertaFasa 1
Umur 1 hingga 30 · Semua jantina · Dikemas kini 17 Jun 2026 · NCT06193759

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.